Theogene Dr Twagirumugabe

Prof. Dr. Theogene Dr Twagirumugabe

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2020 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
ETEugene Tuyishime
Eugene Tuyishime
HIHonorine Ingabire
Honorine Ingabire
JMJean Paul Mvukiyehe
Jean Paul Mvukiyehe
MDMarcel Durieux
Marcel Durieux
TTTheogene Dr Twagirumugabe
Theogene Dr Twagirumugabe
Background: Despite reaching Millennium Development Goal (MDG) 3, the maternal mortality rate (MMR) is still high in Rwanda. Most deaths occur after transfer of patients with obstetric complications from district hospitals (DHs) to referral hospitals; timely detection and management may improve these outcomes. The RI and MEOWS tool has been designed to predict morbidity and decrease delay of transfer. Our study aimed: 1) to determine if the use of the RI and MEOWS tool is feasible in DHs in Rwanda and 2) to determine the role of the RI and MEOWS tool in predicting morbidity. Methods: A cross-sectional study enrolled parturient admitted to 4 district hospitals during the study period from April to July 2019. Data was collected on completeness rate (feasibility) to RI and MEOWS tool, and prediction of morbidity (hemorrhage, infection, and pre-eclampsia). Results: Among 478 RI and MEOWS forms used, 75.9% forms were fully completed suggesting adequate feasibility. In addition, the RI and MEOWS tool showed to predict morbidity with a sensitivity of 28.9%, a specificity of 93.5%, a PPV of 36.1%, a NPV of 91.1%, an accuracy of 86.2%, and a relative risk of 4.1 (95% Confidential Interval (CI), 2.4–7.1). When asked about challenges faced during use of the RI and MEOWS tool, most of the respondents reported that the tool was long, the staff to patient ratio was low, the English language was a barrier, and the printed forms were sometimes unavailable. Conclusion: The RI and MEOWS tool is a feasible in the DHs of Rwanda. In addition, having moderate or high scores on the RI and MEOWS tool predict morbidity. After consideration of local context, this tool can be considered for scale up to other DHs in Rwanda or other low resources settings. Trial registration: This is not a clinical trial rather a quality improvement project. It will be registered retrospectively.

6 January 2017 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
TTTheogene Dr Twagirumugabe
Theogene Dr Twagirumugabe
GSGatare Swaibu
Gatare Swaibu
TWTim Walker
Tim Walker
MLMagnus Lindh
Magnus Lindh
JGJean Bosco Gahutu
Jean Bosco Gahutu
HNHeléne Norder
Heléne Norder
Rwanda is a central African country with about 12 million inhabitants. The 1994 genocide against the Tutsi destroyed much of the infrastructure, including the health system. Although this has improved significantly, many challenges remain to be addressed. In this study, the prevalence of serological markers of past and ongoing hepatitis B virus (HBV) infection and HBV vaccine related immunity was investigated in samples from blood donors from all regions of Rwanda. The results from hepatitis B surface antigen (HBsAg) analyses of all (45,061) blood donations collected countrywide in 2014 from 13,637 first time and 31,424 repeat blood donors were compiled. Samples from 581 HBsAg negative blood donors were selected for further analysis for antibodies against HBV, anti-HBs and anti-HBc. Additional 139 samples from HBsAg positive donors were analyzed for HBeAg/anti-HBe (132 samples) and for HBV DNA. The S-gene was amplified by PCR, products sequenced, and phylogenetic analysis was performed. HBsAg was found in 4.1% of first time donors with somewhat higher prevalence among those from the Central and Eastern regions than from other parts of the country. Indications of past infection was found in 21% of the HBsAg negative donors, 4.3% had only anti-HBs suggesting HBV vaccination. HBeAg was detected in 28 (21%), anti-HBe in 97 (73%), and both HBeAg and anti-HBe in 4 of 132 HBsAg positive donors. HBV DNA was found in 85 samples, and the complete S-gene was sequenced in 58 of those. Phylogenetic analysis of the sequences revealed that all HBV strains belonged to subgenotype A1, and formed one clade in the phylogenetic tree. In addition, 12 strains from first time donors had a unique 18 amino acid deletion in the N-terminal part of the pre-S2 region. This study indicated that the prevalence of hepatitis B is intermediate in Rwanda and that the vaccination coverage is relatively low in young adults. All surveyed Rwandan blood donors were infected with similar subgenotype A1 strains, and a high frequency of those with anti-HBe had detectable HBV DNA. Several strains had in addition a unique pre-S2 deletion, the virulence of which needs to be further studied.

1 September 2019 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
TTTheogene Dr Twagirumugabe
Theogene Dr Twagirumugabe
FSFredy Saguti
Fredy Saguti
SHSylvain Habarurema
Sylvain Habarurema
JGJean Bosco Gahutu
Jean Bosco Gahutu
ABand Tomas Bergström
and Tomas Bergström
HNHeléne Norder
Heléne Norder
To investigate the prevalence of anti-HAV and HEV markers in order to better understand spread of these two viruses among adults in Rwanda. Samples from 1045 and 1133 blood donors, healthy adults and liver disease patients were analysed for anti-HAV IgG and HEV markers respectively. Anti-HAV was present in 96.9% (1013/1045), with proportions of immune persons increasing with age. HEV infection markers were detected in 11.9% (135/1133) without differences between the three categories. Seven persons had low levels of HEV RNA including four blood donors but none of the HEV strains could be sequenced. The highest prevalence of HEV markers was in farmers and persons from the Southern (17.3%) and Western regions (18.6%), which have the national highest density of pigs. This may indicate that pigs constitute an important source of HEV infection for humans in Rwanda. HAV remains highly endemic in Rwanda, but there may now be a decline of exposure during childhood. HEV is also endemic in Rwanda, but has a moderate spread and may be transmitted by blood transfusion. Based on the geographical and occupational differences in HEV prevalence, a possible zoonotic transmission from pigs should be further explored.

MNMenelas Nkeshimana
Menelas Nkeshimana
DIDeborah Igiraneza
Deborah Igiraneza
DTDavid Turatsinze
David Turatsinze
ONOtto NIYONSENGA
Otto NIYONSENGA
DADeborah Abimana
Deborah Abimana
SNSabin Nsanzimana
Sabin Nsanzimana
The management of COVID-19 in Rwanda has been dynamic, and the use of COVID-19 therapeutics has gradually been updated based on scientific discoveries. The treatment for COVID-19 remained patient-centered and entirely state-sponsored during the first and second waves. From the time of identification of the index case in March 2020 up to August 2021, three versions of the clinical management guidelines were developed, with the aim of ensuring that the COVID-19 patients treated in Rwanda were receiving care based on the most recent therapeutic discoveries. As the case load increased and imposed imminent heavy burdens on the healthcare system, a smooth transition was made to enable that the asymptomatic and mild COVID-19 cases could continue to be closely observed and managed while they remained in their homes. The care provided to patients requiring facility-based interventions mainly focused on the provision of anti-inflammatory drugs, anticoagulation, broad-spectrum antibiotic therapy, management of hyperglycemia and the provision of therapeutics with a direct antiviral effect such as favipiravir and neutralizing monoclonal antibodies. The time to viral clearance was observed to be shortest among eligible patients treated with neutralizing monoclonal antibodies (bamlanivimab). Moving forward, as we strive to continue detecting COVID-19 cases as early as possible, and promptly initiate supportive interventions, the use of neutralizing monoclonal antibodies constitutes an attractive and cost-effective therapeutic approach. If this approach is used strategically along with other measures in place (i.e., COVID-19 vaccine roll out, etc.), it will enable us to bring this global battle against the COVID-19 pandemic under full control and with a low case fatality rate.

21 January 2026 in JMIR Formative Research
Verified
Journal Article
Open access
DMDjibril Mbarushimana
Djibril Mbarushimana
TATaofeek Adegboyega
Taofeek Adegboyega
GDGatera Jean Damascene
Gatera Jean Damascene
MBMuritala Issa Bale
Muritala Issa Bale
BDBuregeya Jean Damascene
Buregeya Jean Damascene
NCNgarambe Christian
Ngarambe Christian
Background: Antimicrobial resistance (AMR) poses a significant global health threat, requiring effective antimicrobial susceptibility testing (AST) and surveillance systems. At the University Teaching Hospital of Butare (CHUB) in Rwanda, a baseline Laboratory Assessment of Antibiotic Resistance Testing Capacity (LAARC) identified critical gaps in the Laboratory Information System (LIS), including low capture rates for culture observation (60%) and AST data (25%), no standardization of AST panels (0%), and limited cumulative antibiogram generation (17%). Existing AMR surveillance platforms, such as the Information System for Monitoring Antimicrobial Resistance by the World Health Organization (WHO) Collaborating Center for Surveillance of Resistance to Antimicrobial Agents (WHONET), and the District Health Information System, operate as standalone systems separate from clinical workflows, which limits their real-time clinical utility. Objective: This study aimed to develop an enhanced, web-based LIS integrated within routine clinical care to improve AST reliability, enable real-time AMR surveillance at CHUB, and provide a scalable model for subnational and national surveillance networks in resource-limited settings, supporting antimicrobial stewardship. Methods: We developed an enhanced LIS using the OpenClinic GA, the current open-source hospital information system at CHUB, integrating Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines, and leveraging metadata from the AMR for R package, WHONET resources, and EUCAST Expert Rules. An agile development approach was used, incorporating a custom database schema, Java-based application programming interfaces (APIs), and web-based user interfaces. The system was designed to support minimum inhibitory concentration (MIC) and disk diffusion (DD) methods, automate result interpretation with color-coded outputs, WHO Access, Watch, Reserve (AWaRe)–based cascade reporting, and enable data export to WHONET for global surveillance. Results: The enhanced LIS improved AST data capture and standardization, providing reliable, automated result interpretation and real-time AMR surveillance capabilities. The system’s web-based architecture enables scalability through centralized deployment, allowing multiple facilities simultaneous access. Unlike standalone surveillance tools, the enhanced LIS integrates AST within electronic medical records, maintaining clinical information continuity from specimen registration through result reporting. The system supports immediate clinical decision through AWaRe–based cascade reporting, and automated resistance phenotype detection, followed by standardized WHONET-compatible exports for public health surveillance. Conclusions: This scalable, LIS model demonstrates the feasibility of implementing standards-based AMR informatics in resource-limited settings. By embedding surveillance within clinical workflows rather than treating it as a separate downstream activity, the system maximizes data quality and clinical relevance while minimizing staff burden. The centralized web-based architecture provides inherent scalability from facility to national levels, eliminating data fragmentation and ensuring metadata consistency across networks. Long-term sustainability requires continuous user training, designated personnel for metadata maintenance, local IT capacity building, and funding mechanisms beyond donor dependency. This model provides a practical roadmap for national digital stewardship programs, supporting both immediate patient care and long-term public health surveillance goals.

5 November 2024 in medRxiv
Verified
Preprint
Open access
PDF file
YBYvan Butera
Yvan Butera
LMLeon Mutesa
Leon Mutesa
EPEdyth Parker
Edyth Parker
RMRaissa Muvunyi
Raissa Muvunyi
EUEsperance Umumararungu
Esperance Umumararungu
Claude Mambo MuvunyiClaude Mambo Muvunyi
Claude Mambo Muvunyi
The ongoing outbreak of Marburg virus disease (MVD) in Rwanda marks the third largest historically, though it has exhibited the lowest fatality rate. Genomic analysis has identified a lineage with limited internal diversity most closely related to a genome sequence from a sporadic case sampled in 2014 in Uganda, though the lineages have diverged from a common ancestor that was circulating for decades in the animal reservoir. Notably, the data also provide evidence that the outbreak resulted from a single zoonotic transmission event with limited human-to-human transmission, rather than multiple independent zoonotic transmission events. The Rwandan MVD outbreak prompted a thorough investigation that included contact tracing, clinical assessment, travel history, sequencing, and serology testing, to trace the virus’s origin. Results of investigations linked the index case to a mining cave inhabited by Rousettus aegyptiacus (the Egyptian fruit bat), where three individuals tested seropositive for IgG and IgM, further supporting the zoonotic origin of the outbreak through human-animal interactions.